Current Evidence and Therapeutic Strategies for Multiple Sclerosis

Dean M. Wingerchuk, M.D., M.Sc., F.R.C.P.(C.)¹

The publisher regrets an error in the text of the above article in *Seminars in Neurology*, Volume 28, Number 1, 2008, p. 65. In the last paragraph, at the bottom of the first column, the text reads as follows:

Progressive multifocal leukoencephalopathy has also emerged in association with rituximab therapy for **rheumatoid arthritis**, typically in patients exposed to other immunosuppressive agents.⁸⁶

The corrected text should read as follows:

Progressive multifocal leukoencephalopathy has also emerged in association with rituximab therapy for **systemic lupus erythematosus**, typically in patients exposed to other immunosuppressive agents.⁸⁶

¹Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona.

Address for correspondence and reprint requests: Dean M. Wingerchuk, M.D., M.Sc., F.R.C.P.(C.), Department of Neurology, Mayo Clinic College of Medicine, 13400 E Shea Boulevard, Scottsdale, AZ 85259 (e-mail: wingerchuk.dean@mayo.edu).

Multiple Sclerosis and the Spectrum of CNS Inflammatory Demyelinating Diseases; Guest Editor, Claudia F. Lucchinetti, M.D.

Semin Neurol 2008;28:389–389. Copyright © 2008 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI 10.1055/s-0028-1082952. ISSN 0271-8235.